OMER

8.83

0.74% 0.065

Handel nachbörslich: 8.96 0.13 +1.47%

Omeros Corporation (OMER)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$8.765

Offen:

$8.8

24-Stunden-Volumen:

1.36M

Relative Volume:

0.39

Marktkapitalisierung:

$626.05M

Einnahmen:

Nettoeinkommen (Verlust:

$-117.81M

KGV:

-4.6968

EPS:

-1.88

Netto-Cashflow:

$74.30M

1W Leistung:

-21.44%

1M Leistung:

-2.75%

6M Leistung:

+175.08%

1J Leistung:

+12.06%

1-Tages-Spanne:

$8.7187

$9.2989

1-Wochen-Bereich:

$8.27

$11.42

52-Wochen-Spanne:

$2.95

$13.60

Omeros Corporation Stock (OMER) Company Profile

Firmenname

Omeros Corporation

Sektor

Healthcare (1133)

Branche

Biotechnology (632)

Telefon

206-676-5000

Adresse

201 ELLIOTT AVENUE WEST, SEATTLE, WA

Mitarbeiter

202

Twitter

@OmerosCorp

Nächster Verdiensttermin

2025-08-08

Neueste SEC-Einreichungen

OMER's Discussions on Twitter

Vergleichen Sie OMER mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OMER Omeros Corporation	8.83	621.44M	0	-117.81M	74.30M	-1.88
VRTX Vertex Pharmaceuticals Inc	449.52	115.43B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	749.79	78.44B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	862.05	52.42B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	392.10	51.68B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	198.46	42.80B	447.02M	-1.18B	-906.14M	-6.1812

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-10	Eingeleitet	H.C. Wainwright	Buy
2024-12-23	Eingeleitet	D. Boral Capital	Buy
2024-11-14	Eingeleitet	Rodman & Renshaw	Buy
2022-12-08	Herabstufung	UBS	Buy → Neutral
2022-11-08	Herabstufung	BofA Securities	Neutral → Underperform
2022-06-08	Herabstufung	BofA Securities	Buy → Neutral
2021-10-08	Herabstufung	JP Morgan	Neutral → Underweight
2021-10-01	Herabstufung	Maxim Group	Buy → Hold
2021-10-01	Herabstufung	Wedbush	Neutral → Underperform
2021-09-27	Eingeleitet	JP Morgan	Neutral
2021-02-01	Eingeleitet	UBS	Buy
2020-10-20	Eingeleitet	BofA Securities	Buy
2020-08-21	Bestätigt	H.C. Wainwright	Buy
2020-08-14	Bestätigt	Maxim Group	Buy
2019-05-06	Eingeleitet	Cantor Fitzgerald	Overweight
2018-07-12	Eingeleitet	Seaport Global Securities	Buy
2018-03-23	Herabstufung	Wedbush	Outperform → Neutral
2018-03-05	Herabstufung	Needham	Buy → Hold
2017-11-08	Eingeleitet	H.C. Wainwright	Buy
2017-05-11	Herabstufung	Cantor Fitzgerald	Buy → Neutral
2017-03-17	Bestätigt	Maxim Group	Buy
2017-03-17	Bestätigt	Needham	Buy
2016-11-16	Bestätigt	Wedbush	Outperform
2016-11-10	Bestätigt	Needham	Buy
2016-08-10	Bestätigt	Maxim Group	Buy
2016-06-03	Eingeleitet	Cantor Fitzgerald	Buy
2016-03-02	Bestätigt	Needham	Buy
2016-02-29	Bestätigt	Wedbush	Outperform
2015-11-11	Bestätigt	Needham	Buy
2015-08-18	Bestätigt	WBB Securities	Strong Buy
2015-08-10	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Omeros Corporation Aktie (OMER) Neueste Nachrichten

Dec 16, 2025

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN

Dec 16, 2025

Dec 13, 2025

Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval? - Insider Monkey

Dec 08, 2025

Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 08, 2025

Dec 06, 2025

Omeros Completes Major Asset Deal with Novo Nordisk - MSN

Dec 06, 2025

Dec 05, 2025

Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? - MSN

Dec 05, 2025

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN

Dec 05, 2025

Dec 04, 2025

Omeros (NASDAQ:OMER) Stock Price Up 8.2%Still a Buy? - MarketBeat

Dec 04, 2025

Can Omeros Corporation stock outperform in 2025 bull marketJuly 2025 Update & Short-Term High Return Ideas - Newser

Dec 04, 2025

Omeros Corporation's (NASDAQ:OMER) Surges Amid Clinical Advancements - Kalkine Media

Dec 04, 2025

Dec 02, 2025

Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital - MarketBeat

Dec 02, 2025

Omeros Shares Jump After Finalizing $340 Million Novo Nordisk Deal - MSN

Dec 02, 2025

Aug Sentiment: Is Omeros Corporation stock attractive for income investorsMarket Volume Report & Smart Allocation Stock Tips - moha.gov.vn

Dec 02, 2025

How Omeros Corporation stock performs in weak economyChart Signals & Entry Point Confirmation Alerts - Newser

Dec 02, 2025

Dec 01, 2025

Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Cap - GuruFocus

Dec 01, 2025

Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - MSN

Dec 01, 2025

Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus

Dec 01, 2025

Omeros Closes Asset Purchase, Licensing Deal With Novo Nordisk for Zaltenibart - MarketScreener

Dec 01, 2025

Omeros, Novo Nordisk Close Up to $2.1B Deal for Rare Disease Drug Zaltenibart, NOVO Stock - Somos Hermanos -

Dec 01, 2025

Omeros receives $240 million upfront from Novo Nordisk deal By Investing.com - Investing.com Canada

Dec 01, 2025

Omeros receives $240 million upfront from Novo Nordisk deal - Investing.com

Dec 01, 2025

Omeros stock surges after closing $340 million deal with Novo Nordisk - Investing.com Australia

Dec 01, 2025

Omeros stock surges after closing $340 million deal with Novo Nordisk By Investing.com - Investing.com South Africa

Dec 01, 2025

Omeros closes asset purchase and license deal with Novo Nordisk for MASP-3 inhibitor zaltenibart - marketscreener.com

Dec 01, 2025

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Yahoo Finance

Dec 01, 2025

Nov 29, 2025

Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - simplywall.st

Nov 29, 2025

Nov 28, 2025

What catalysts could drive Omeros Corporation stock higher2025 Short Interest & Weekly Top Stock Performers List - moha.gov.vn

Nov 28, 2025

Nov 27, 2025

Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN

Nov 27, 2025

Nov 26, 2025

Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat

Nov 26, 2025

Nov 21, 2025

Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha

Nov 21, 2025

What technical signals suggest for Omeros Corporation stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com

Nov 21, 2025

Nov 20, 2025

Omeros Corporation Stock Analysis and ForecastInsider Selling Patterns & Free Stock Trading Workshops - earlytimes.in

Nov 20, 2025

Is Omeros Corporation stock cheap compared to fundamentalsIPO Watch & Technical Entry and Exit Tips - newser.com

Nov 20, 2025

Nov 19, 2025

Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN

Nov 19, 2025

Omeros (NASDAQ:OMER) Shares Down 5.6%Should You Sell? - MarketBeat

Nov 19, 2025

Here's Why Shares in Theravance Biopharma Exploded Today - AOL.com

Nov 19, 2025

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com

Nov 19, 2025

How strong is Omeros Corporation stock revenue growthBuy Signal & Fast Exit/Entry Strategy Plans - newser.com

Nov 19, 2025

Finanzdaten der Omeros Corporation-Aktie (OMER)

Umsatz

Nettogewinn

Free Cashflow

ENV

RPRX

$38.31

0.18%

INCY

$97.63

0.62%

GMAB

$31.71

1.15%

BNTX

$91.60

0.68%

ONC

$306.05

0.57%

INSM

$198.46

1.10%

Omeros Corporation (OMER)

Omeros Corporation Stock (OMER) Company Profile

Vergleichen Sie OMER mit anderen Aktien

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Omeros Corporation Aktie (OMER) Neueste Nachrichten

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN

Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat

Omeros (NASDAQ:OMER) Trading Down 5.1%Here's What Happened - MarketBeat